Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it ...

In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based ...

Merck (NYSE:MRK) has agreed to acquire Terns Pharmaceuticals in a deal aimed at expanding its oncology and hematology ...

By Siddhi Mahatole March 25 (Reuters) - Merck said on Wednesday it would buy biotech firm Terns Pharma for $6.7 billion, as ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health ...

The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV ...

The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Two stocks retirement investors typically reach for in uncertain markets have risen notably in recent months. Is it too late to buy?

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens ...

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Consistent Dividend Stocks to Buy Right Now. On April 6, JPMorgan analyst Chris Schott raised the firm’s price recommendation on Merck & Co., ...